Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC

NCT02954172 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Bevacizumab in Combination With Paclitaxel/Carboplatin
DRUG: IBI305 in Combination with Paclitaxel/Carboplatin

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Collaborators

[object Object]